Open AccessPhase I Study of the BRAF Inhibitor Vemurafenib in Combination With the Mammalian Target of Rapamycin Inhibitor Everolimus in Patients With BRAF-Mutated Malignancies
Author(s) -
Vivek Subbiah,
Shiraj Sen,
Kenneth R. Hess,
Filip Janků,
David S. Hong,
Soumen Khatua,
Daniel D. Karp,
Javier Muñoz,
Gerald S. Falchook,
Roman Groisberg,
Apostolia M. Tsimberidou,
Steven I. Sherman,
Patrick Hwu,
Funda MericBernstam
Publication year - 2018
Publication title -
jco precision oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.405
H-Index - 22
ISSN - 2473-4284
DOI - 10.1200/po.18.00189
Subject(s) - vemurafenib , everolimus , discovery and development of mtor inhibitors , medicine , cancer research , oncology , pharmacology , pi3k/akt/mtor pathway , melanoma , biology , metastatic melanoma , signal transduction , genetics
Parallel activation of the phosphatidylinositol 3-kinase-mammalian target of rapamycin pathway represents a mechanism of primary and acquired resistance to BRAF-targeted therapy, but the two pathways have yet to be cotargeted in humans. We performed a phase I study to evaluate the safety and activity of the BRAF inhibitor vemurafenib in combination with the mammalian target of rapamycin inhibitor everolimus in BRAF -mutated advanced solid tumors.